Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Can someone explain

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Oct 15, 2023 8:56am

90 Views

Post# 35684205

RE:RE:RE:RE:Can someone explain

It would be helpful if you could elaborate rather than simply saying it's false.

jfm1330 wrote: It's not helpful at all, it's all false.

PWIB123 wrote: Thanks Scarlet1967. That's helpful. I was wondering what a road map would look like. I wasn't even sure if their statement about meeting with experts was a certainty that they would get a second shot at it. I'm assuming they will, but it was unclear to me as someone who doesn't have any experience working in this space. I hope they update that roadmap super quick and be extremely clear about the details of each step.